TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
TAKEDA PHARMACEUTICAL CO LTD
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026
$19.61−0.06 (-0.31%)
Close on Oct 19, 2026
Share price
+$5.57 (+39.67%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
TAKEDA PHARMACEUTICAL CO LTD saw revenue fall 1.7% to ¥4.51T over fiscal 2026. Operating income fell 98.2% to ¥6.22B, moving the operating margin from 7.5% to 0.1%. Free cash flow was ¥865.43B, up 1.1% from a year earlier.
Revenue
¥4.51T
-1.7% vs. a year earlier
Operating income
¥6.22B
-98.2% vs. a year earlier
Free cash flow
¥865.43B
+1.1% vs. a year earlier
EPS, diluted
-96.75 JPY
-243.9% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Mar 31, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- ¥4.51T
- Net income
- -¥152.39B
- EPS, diluted
- -96.75 JPY
- Free cash flow
- ¥865.43B
Valuation needs the share price. It fills in once daily prices are connected and converted from JPY.
Eleven years at a glance
Fiscal years 2016 to 2026, JPY
Revenue
¥4.51T-1.7% YoY
Gross profit
¥2.93T-2.2% YoY
Operating income
¥6.22B-98.2% YoY
Net income
-¥152.39B-241.2% YoY
EPS, diluted
-96.75 JPY-243.9% YoY
Free cash flow
¥865.43B+1.1% YoY
Reported period